AI Tools Stumped By HER2-Low Breast Cancer Just Like Pathologists, Study Finds

A study evaluated agreement between 10 AI digital pathology tools in assessing IHC-based HER2 expression and found the most variability in identifying HER2-low samples.

UCSD Scientists Report Early Success With Cystinosis Gene Therapy in First-in-Human Trial

The gene therapy, which was acquired by Novartis in 2023, is also being tested in a separate Phase I/II trial of pediatric patients.

When Even Basic Care Is Lacking in Indigenous Communities, What Does Precision Medicine Look Like?

Distance, lack of coverage, and mistrust have limited Indigenous patients' access to basic and advanced medicine, but cancer centers are embracing strategies to change that.

Minneapolis Genetics Professionals Speak Out on Public Health Harms of ICE Crackdown

Federal immigration enforcement action may be winding down, but healthcare professionals say the "collective trauma" ICE inflicted on the community will be long lasting.

When Even Basic Care Is Lacking in Indigenous Communities, What Does Precision Medicine Look Like?

Distance, lack of coverage, and mistrust have limited Indigenous patients' access to basic and advanced medicine, but cancer centers are embracing strategies to change that.

Amid Flu Vaccine Turmoil, Moderna Expects Strong Oncology Data in 2026

The company is expecting additional readouts this year from studies of cancer vaccine intismeran autogene, which is being tested in late-stage trials.

Vertex, CRISPR Therapeutics Record $115.8M in 2025 Casgevy Sales

Vertex posted revenue and earnings for Q4 and full-year 2025 that hovered around consensus Wall Street estimates, but CRISPR Therapeutics missed expectations.

With $39M in Series A Funding, Irish Biotech Aerska Aims to Deliver RNAi Drugs to the Brain

The firm is developing RNAi drugs to treat neurological diseases by silencing genes in the brain, the first of which it will nominate this year.

Anixa Testing Ovarian Cancer CAR-T Therapy at Higher Doses

The firm will test the FSHR-targeting lira-cel at up to 100-tmes higher doses after seeing better than expected outcomes at lower doses in a Phase I trial.

Gilead's Cell Therapy Sales Tumble for Third Quarter in a Row

The company is continuing to prepare for a second half rollout of anito-cel if it is approved by the FDA.

AstraZeneca Records 22 Percent Growth in Q4 Oncology Business as Precision Drug Sales Surge

Tagrisso, Imfinzi, Truqap, and Enhertu all reported double-digit sales growth during the fourth quarter and full-year 2025 versus the same periods in 2024.

Anixa Testing Ovarian Cancer CAR-T Therapy at Higher Doses

The firm will test the FSHR-targeting lira-cel at up to 100-tmes higher doses after seeing better than expected outcomes at lower doses in a Phase I trial.

Biogen Holds on to Leqembi Lead in Overall Anti-Amyloid Market, Bolstered by Maintenance Indication

Biogen's "growth products" — about a half-dozen products including Leqembi — contributed $800 million to the firm's $2.28 billion in Q4 2025 revenue.

Alzheimer's Patients May Benefit From New Drugs, Collaborative Program Integration, UCSF Finds

Dementia care isn't just about new drugs, said the author of a cost-effectiveness study comparing collaborative care, Leqembi, or combining both.

Alzheimer's Patients May Benefit From New Drugs, Collaborative Program Integration, UCSF Finds

Dementia care isn't just about new drugs, said the author of a cost-effectiveness study comparing collaborative care, Leqembi, or combining both.

Eli Lilly Drops Frontotemporal Dementia Gene Therapy; Touts Kisunla as Anti-Amyloid Leader

The firm provided updates alongside Q4 and full-year 2025 financial results, and reported $19.29 billion and $65.18 billion in revenue, respectively.

Transgene Moving Personalized Vaccine to Phase II, Eyeing Trial Sites in US, Canada

The company is advancing TG4050 in head and neck cancer and possibly to other tumor types based on encouraging Phase I data.

Pfizer Reports 9 Percent Increase in Q4 Oncology Revenue as Ibrance Patent Cliff Looms

Despite another quarter of declining sales for Ibrance, its top-selling oncology drug, revenue for Pfizer's overall oncology portfolio increased 9 percent year over year.

Merck Pushes Back on Slowdown Assumptions, Defends Oncology Pipeline Potential

The firm missed Wall Street Q4 revenue estimates but assured steady growth as it plans for Keytruda's patent expirations, a deadline it hopes to hold off a bit longer.

CIRM Earmarks $100M For Rare Disease Platform Therapies in New RAPID Program

CIRM will fund validation awards to bring therapies to human trials and innovation awards to those that "push the boundaries" of platform approaches.

Eli Lilly Expanding Hearing Loss Gene Therapy Push With $1B Seamless Therapeutics Pact

Lilly will license programmable recombinases developed by Seamless to create new gene-editing therapies that could treat genetic hearing loss.

Advocacy Groups Challenge NICE Decision to Limit Tecartus Access in England, Wales

Three blood cancer organizations have appealed a NICE draft guidance, which could make the therapy unavailable for mantle cell lymphoma patients.

Caring Cross Plans Sickle Cell Gene Therapy Trials in India, Brazil While Amassing Data for FDA

The nonprofit biotech recently licensed the gene therapy from Boston Children's Hospital and plans to bring it to low- and middle-income countries.

Four-Biomarker Blood Test Could Improve Early Pancreatic Cancer Detection

The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.

Four-Biomarker Blood Test Could Improve Early Pancreatic Cancer Detection

The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.

Roche Anticipating Giredestrant Approval in 2026, Touts 'Discipline' and 'Stability'

Sales rose 2 percent overall in 2025, driven by the strong performance of several oncology drugs, including greater uptake of HER2 treatment Phesgo.

Four-Biomarker Blood Test Could Improve Early Pancreatic Cancer Detection

The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.

Four-Gene Blood Biomarker Test Could Improve Early Pancreatic Cancer Detection

The panel, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.

Roche Anticipating Giredestrant Approval in 2026, Touts 'Discipline' and 'Stability'

Sales rose 2 percent overall in 2025, driven by the strong performance of several oncology drugs, including greater uptake of HER2 treatment Phesgo.

Huntington's Groups Urge FDA to Review UniQure's Gene Therapy

UniQure had planned to seek accelerated approval for AMT-130 early 2026, but then said its plans were stalled after unexpected FDA feedback.